Ayala Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Ayala Pharmaceuticals's estimated annual revenue is currently $3.9M per year.
- Ayala Pharmaceuticals's estimated revenue per employee is $100,500
- Ayala Pharmaceuticals's total funding is $72M.
- Ayala Pharmaceuticals has 39 Employees.
- Ayala Pharmaceuticals grew their employee count by 3% last year.
Ayala Pharmaceuticals Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Ayala Pharmaceuticals?
Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Our differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of our bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The companyￃﾢ￢ﾂﾬ￢ﾄﾢs product candidates, AL101 and AL102, were licensed into Ayala from Bristol Myers Squibb. Our lead product candidate AL101 is currently in Phase 2 clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma, for patients bearing Notch-activating mutations. Our second product candidate AL102 is being developed for the treatment of desmoid tumors. In addition, we are collaborating with Novartis to develop AL102 for the treatment of multiple myeloma in combination with Novartisￃﾢ￢ﾂﾬ￢ﾄﾢ B-cell maturation antigen (BCMA) targeting therapies. The company is based in the US and Israel.keywords:N/A
Number of Employees
Employee Growth %
Ayala Pharmaceuticals News
raised its stake in Ayala Pharmaceuticals by 406,248.7% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns...
Ayala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update. - Part A of AL102 RINGSIDE study fully enrolled;...
REHOVOT, Israel and WILMINGTON, Del., March 28, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Ayala or the Company) (Nasdaq: AYLA),...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|